๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Unresectable Hepatocellular Carcinoma
Clinical trial register · China

Unresectable Hepatocellular Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Nanjing 6 Guangzhou 5 Wuhan 4 Chengdu 3 Tianjin 2
Narrow the registerReset
Recruitment status
Phase
Site location
Nanjing6 Guangzhou5 Wuhan4 Chengdu3 Tianjin2
All 15 locations
Target enrolment
to

Unresectable Hepatocellular Carcinoma trials in China

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
NCT07729618Unresectable Hepatocellular Carcinoma
Tongji Hospital
Not applicable
1,800
Wuhan
2026-10-01
Not yet open
Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
NCT07824765Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Observational
2,658
Nanjing
2026-09-01
Recruiting
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
NCT07482059Unresectable Hepatocellular Carcinoma
West China Hospital
Phase 1/2
33
Chengdu
2026-02
Not yet open
HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
NCT07045558Unresectable Hepatocellular Carcinoma
RenJi Hospital
Observational
28
Shanghai
2025-08-01
Recruiting
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
NCT07806292Unresectable Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
30
Guangzhou
2025-04-28
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xiโ€™an, Chengdu
2025-04-15
Recruiting
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
NCT06909708Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
108
Nanjing
2025-04-03
Not yet open
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
NCT06896396Unresectable Hepatocellular Carcinoma
Zhiyong Huang
Phase 1/2
60
Wuhan
2025-04-01
Recruiting
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
NCT06593964Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
188
Nanjing
2024-09-10
Recruiting
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT06485466Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
Guohui Xu
Phase 3
101
Chengdu
2024-08-10
Recruiting
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
NCT06280313Unresectable Hepatocellular Carcinoma
Zhiyong Huang
Observational
60
Wuhan
2024-03-15
Recruiting
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
NCT06360042Unresectable Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
111
Beijing
2024-01-01
Recruiting
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
NCT05917431Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Peking University Cancer Hospital & Institute
Phase 2
39
Beijing
2023-06
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
NCT06788353Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Observational
500
Guangzhou
2023-03-01
Active, closed
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
NCT05507632Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2
48
Guangzhou
2022-08-18
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
NCT07204327Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Observational
1,136
Nanjing
2020-10-28
Active, closed
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer
NCT07298538Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Observational
800
Tianjin
2019-01-01
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/unresectable-hepatocellular-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Unresectable Hepatocellular Carcinoma.

How many Unresectable Hepatocellular Carcinoma trials are recruiting in China?

9 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Unresectable Hepatocellular Carcinoma), 20 studies
PhaseStudiesRecruitingShare
Observational8240%
Phase 24320%
Not applicable3215%
Phase 33115%
Phase 1/22110%

Most active sponsors

Lead sponsors with the most studies (Unresectable Hepatocellular Carcinoma)
Lead sponsorStudiesRecruiting
Zhongda Hospital52
Peking University Cancer Hospital & Institute22
Zhiyong Huang21
Bayer10
Chengdu New Radiomedicine Technology Co. LTD.10
Guohui Xu11
Hoffmann-La Roche10
Nanfang Hospital, Southern Medical University10
RenJi Hospital10
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.